Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;129(1):10-17.
doi: 10.1002/jso.27528. Epub 2023 Nov 23.

What's new in surgical oncology breast

Danielle E Brabender  1   2 , V Suzanne Klimberg  3 , Stephen F Sener  1   2
Affiliations
Review

What's new in surgical oncology breast

Danielle E Brabender et al. J Surg Oncol. 2024 Jan.

Abstract

It is on the backdrop of advances in tumor biology and systemic therapy for breast cancer, that progress in locoregional treatment has focused on management of the breast for invasive cancer, imaging for staging and therapeutic decision-making, and de-escalation in the management of the axilla.

Keywords: Breast Surgical Oncology; regional node irradiation; surgical management of axilla.

PubMed Disclaimer

References

REFERENCES

    1. Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. The Breast. 2016;29:241-250. doi:10.1016/j.breast.2016.07.015
    1. Turner N, Marme F, Kim S-B, et al. Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: analysis from the PENELOPE-B trial. 2023 annual ASCO meeting, presentation by turner N. June 1-4, 2023. Chicago, Illinois, USA. J Clin Oncol. 2023;41(no.16_suppl):502. doi:10.1200/JCO.2023.41.16_suppl.502
    1. Cabel L, Delaloge S, Hardy-Bessard AC, et al. Dynamics and type ofESR1mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial. J Clin Oncol. 2023;41(no.16_suppl):1002. doi:10.1200/JCO.2023.41.16_suppl.1002
    1. Pistilli B, Lohrisch C, Sheade J, Fleming GF. Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer. American Soc Clin Oncol Educat Book. 2022;42:60-72. doi:10.1200/EDBK-350358
    1. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663

LinkOut - more resources